Safety and efficacy of entecavir in adefovir-experienced patients

Background and Aim Suboptimal viral suppression with adefovir (ADV) poses a challenge in managing chronic hepatitis B. Few studies have evaluated the efficacy of entecavir (ETV) in ADV‐experienced patients. Our aim is to assess treatment effectiveness of ETV in ADV‐experienced patients. Methods ADV‐...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of gastroenterology and hepatology 2015-01, Vol.30 (1), p.43-50
Hauptverfasser:	Nguyen, Nghia H, Trinh, Huy N, Nguyen, Thuan T, Do, Son T, Tran, Phuong, Nguyen, Huy A, Nguyen, Khanh K, Garcia, Ruel T, Lutchman, Glen A, Nguyen, Mindie H
Format:	Artikel
Sprache:	eng
Schlagworte:	adefovir resistance Adenine - analogs & derivatives Adenine - therapeutic use Adult Alanine Transaminase - blood Antiviral Agents - therapeutic use Biomarkers - blood Drug Substitution Female Follow-Up Studies HBeAg HBV Hepatitis B, Chronic - diagnosis Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology Humans Lamivudine - therapeutic use lamivudine experienced Male Middle Aged Multivariate Analysis Organophosphonates - therapeutic use Time Factors Treatment Outcome Viral Load viral suppression
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background and Aim Suboptimal viral suppression with adefovir (ADV) poses a challenge in managing chronic hepatitis B. Few studies have evaluated the efficacy of entecavir (ETV) in ADV‐experienced patients. Our aim is to assess treatment effectiveness of ETV in ADV‐experienced patients. Methods ADV‐experienced patients switched to ETV were enrolled from six US clinics. Patients completed a median of 24 months of ETV after switch. Patients were categorized into partial responders (detectable HBV‐DNA at switch) or complete responders (undetectable HBV‐DNA at switch) to ADV. Primary and secondary outcome measurements were complete viral suppression (CVS, HBV‐DNA
ISSN:	0815-9319 1440-1746
DOI:	10.1111/jgh.12728